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Abstract
Background: Patients who receive highly variable doses of warfarin may be at risk for poor anticoagulation control
and adverse events. However, we lack a system to identify patients with the highest dose variability. Our objectives
were to develop a scoring system to identify patients with high dose variability, and to validate this new measure
by demonstrating that patients so identified have poor anticoagulation control and higher rates of adverse events
(criterion validity).
Methods: We used a database of over 4, 000 patients who received oral anticoagulation in community practice
between 2000-2002. We reviewed the charts of 168 patients with large warfarin dose variation and agreed on 18
risk factor definitions for high dose variability. We identified 109 patients with the highest dose variability (cases), as
measured by coefficient of variation (CoV, SD/mean). We matched each case to two controls with low dose
variability. Then, we examined all 327 charts, blinded to case/control status, to identify the presence or absence of
the 18 risk factors for dose variability. We performed a multivariable analysis to identify independent predictors of
high CoV. We also compared anticoagulation control, as measured by percent time in therapeutic range (TTR), and
rates of adverse events between groups.
Results: CoV corresponded with other measures of anticoagulation control. TTR was 53% among cases and 79%
among controls (p < 0.001). CoV also predicted adverse events. Six cases experienced a major hemorrhage versus 1
control (p < 0.001) and 3 cases had a thromboembolic event versus 0 control patients (p = 0.04). Independent
predictors of high dose variability included hospitalization (OR = 21.3), decreased oral intake (OR = 12.2), use of
systemic steroids (OR = 6.1), acetaminophen (OR = 4.0) and antibiotics (OR = 2.7; p < 0.05 for all).
Conclusion: CoV can be used to identify patients at risk for poor anticoagulation control and adverse events. This
new measure has the potential to identify patients at high risk before they suffer adverse events.
Keywords: anticoagulants, dose variability, medication therapy management, risk factors, warfarin.
Background
Warfarin is the standard anticoagulation treatment for
atrial fibrillation, venous thromboembolism (VTE), and
mechanical heart valves [1-4]. Close monitoring of the
International Normalized Ratio (INR) is required due to
the drug’s very narrow therapeutic window. Many factors
can affect INR levels [1,5,6]. Values must be kept within
range to reduce the risk of hemorrhage [7,8] and the risk
of developing thromboembolism [9]. Previous studies
have shown that patients experiencing better anticoagula-
tion control have fewer such adverse events [10-14].
Assessment of adequate anticoagulation control has
traditionally been determined by examining INR values
themselves, through summary statistics such as percent
time in therapeutic range (TTR) [15] or INR variability
[16,17]. Several studies have explored the patient-level
predictors of control as measured by TTR [10,18,19].
However, there is reason to believe that variability in
warfarin doses could also serve to identify patients who
are experiencing poorly controlled anticoagulation, thus
placing them at risk for adverse events.
We therefore used a large, nationally representative
database of community-based oral anticoagulation care
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develop a measure of warfarin dose variability that could
be used to describe a population and identify patients
with highly variable doses over time. Second, we sought
to internally validate this new dose variability score as a
measure of anticoagulation control using criterion valid-
ity. That is, we sought to demonstrate that patients
identified as having high dose variability have worse
anticoagulation control as measured by TTR and are at
higher risk for adverse events than patients with less
variability. Finally, through chart review, we sought to
identify patient-level predictors of high dose variability.
Our overarching goal was to develop a score that could
be used to identify patients at high risk for complications.
Methods
Database
The Anticoagulation Consortium to Improve Outcomes
Nationally (ACTION) study was a large prospective cohort
study designed to assess the management of warfarin in
community practice within the US [19-21]. A total of 101
participating sites in 31 states recruited 6761 patients
receiving long-term oral anticoagulation. All sites used a
f r e e l y - a v a i l a b l es o f t w a r ep a c k a g ec a l l e dC o u m a C a r ef o r
tasks such as patient tracking and recording clinical data.
In the database, clinicians updated patient’s weekly war-
farin dose at each visit. Because the present study relied
upon chart reviews, we limited this study to the 47 sites of
care that recorded complete notes for at least 90% of INR
values. Excluded sites recorded notes only when the INR
was not therapeutic. Therefore, this study was limited to
4489 patients.
Enrollment in ACTION occurred between April 2000
and February 2002. Patients were eligible to participate if
they were 18 years or older and able to provide informed
consent. All data were collected and their completeness
rigorously ensured by McKesson HBOC, an independent
data management organization. Missing data fields and
data entry errors were resolved directly with the sites by
the data coordinating center on a weekly basis before the
data were transmitted to study investigators. The study
protocol was approved by the Western Institutional
Review Board of Olympia, WA, and by local review
boards where they existed.
Patients were eligible for inclusion in the present study if
they had an INR target range of 2-3. Indications for antic-
oagulation were grouped as follows: atrial fibrillation,
venous thromboembolism, valvular heart disease/prosthe-
tic heart valve, and all others. The database included
demographics (age, gender, and race) and several comor-
bid conditions (coronary artery disease, congestive heart
failure, hypertension, diabetes) as recorded by the patients’
clinicians. Weekly dose of warfarin was recorded for all
patients in the database, and was updated by clinicians at
each visit. We used these weekly doses to assess the stabi-
lity of warfarin dose over time for each patient, as will be
explained below.
Chart Reviews
We performed two separate chart reviews, in our efforts to
create a score that describes patients with high warfarin
dose variability. The first review was implicit; it was per-
formed by chart reviewers without relying upon pre-estab-
lished definitions. Three physician examiners (LM, ME,
and AJR) independently reviewed the charts of 168
patients who had a 2-fold or greater difference between
the lowest and highest weekly warfarin dose (e.g. 14 mg/
week versus 28 mg/week). The concept behind the review
was to remain open to the possibilities of factors that may
be present in the database rather than rely solely upon
preconceived ideas. Next, the reviewers met and compiled
a list of 18 variables believed to have played the greatest
role in the dose variability. They reached a consensus
regarding a standard definition for each variable in the
chart review instrument (Table 1).
We found that the criterion used to identify patients
with high dose variability (i.e. twofold or greater dose
range) did not capture the dose variability we had in mind.
Specifically, the method identified a relatively large pro-
portion of patients with one or two outlier doses but
otherwise stable dosing. Not all of the patients identified
by this score seemed to be experiencing the highly variable
anticoagulation control that we were trying to capture. We
therefore decided to use the coefficient of variation (CoV)
to characterize warfarin dose variability. CoV is defined as
the standard deviation of the weekly warfarin dose divided
by the mean weekly warfarin dose.
We labeled all patients with CoV greater than 0.2 as
patients with high dose variation ("cases”). There were
123 such patients, representing 2.7% of the dataset.
Patients with CoV below 0.05 (1019 patients, represent-
ing 23% of the dataset) were eligible to be controls. Each
case was matched to 2 controls within the same site of
care. Charts were excluded if: 1) there were no controls
available to match the case patients or 2) the patient was
new to warfarin (less than 1 month experience as of
study entry). A total of 14 cases and 12 potential controls
were removed for these reasons, leaving 109 cases and
218 controls.
The reviewers then independently reviewed charts to
identify the 18 variables defined in the chart review instru-
ment. This second review was explicit in that it relied
upon the variable definitions described in the instrument.
During this second chart review, reviewers were blinded to
whether the patient was a case or a control patient. If a
factor was present at any time, we recorded this indicator
as “1” (present) versus “0” (not present). Each reviewer
abstracted one-third of the charts. Fifty of the charts were
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agreement.
Adverse Events
Ischemic stroke/systemic arterial embolism, VTE and
major hemorrhage were the adverse outcomes of interest.
We defined major hemorrhage according to the defini-
tion of the International Society of Thrombosis and Hae-
mostasis: a fatal event, an event requiring hospitalization
with transfusion of at least two units of packed red blood
cells, or bleeding involving a critical anatomical site such
as the cranium or the retroperitoneum [22]. All patient
progress notes were individually reviewed for evidence of
adverse events; events were validated directly with the
sites by McKesson.
Statistical Analyses
Kappa () statistics were computed to assess inter-rater
r e l i a b i l i t yf o rt h es e c o n dc h a rt review. To assess signifi-
cance of effects when comparing categorical variables with
the matched design, we used Monte Carlo permutation
methods with 10, 000 iterations to compute empirical p-
values. Case-control status within each “cluster” of
matched observations was randomly permuted 10, 000
times, with a test statistic (e.g., Pearson’s chi-square statis-
tic) calculated upon each iteration. This was used as a
reference distribution, under the null hypothesis of no
association with case status, to compute the empirical
p-value. Groups were compared on continuous variables
using a generalized linear model to account for correlation
between each case and its matched controls. We used con-
ditional logistic regression models to determine the factors
that independently predict case status while controlling for
patient level covariates (i.e. age, gender, race, co-morbid
conditions). Analyses were performed using SAS, version
9.1 (SAS Corporation) and R, version 2.8 (R Foundation).
Results
Baseline Characteristics
There were 109 cases with high dose variability and 218
site-matched controls with low dose variability (Table 2).
The mean coefficient of variation (CoV) of the cases was
0.24 and the mean for the controls was 0.02 (p < 0.001).
The two groups were similar in demographics: most par-
ticipants were white (89% of cases and 94% of controls)
and many were 75 years of age or older (50% of cases and
42% of controls). Forty-five percent of cases were female,
compared to 32% of controls (p = 0.02). Atrial fibrillation
Table 1 Chart Review Instrument
Variable Definition
1 Diet Any mention of “greens”, specific foods high in vitamin K, and dietary content of vitamin K. DOES NOT
INCLUDE statements that the vitamin K content of the diet is unchanged.
2 Dietary Supplements Any mention of multivitamins, Ensure, Boost, Slimfast, etc. as they relate to vitamin K intake. DOES NOT
INCLUDE simply listing a multivitamin in the medication list.
3 Adherence Any mention of problems with adherence to pill-taking, including unauthorized self-adjustment of doses and
memory issues. DOES NOT INCLUDE dose confusion after a hospital stay and DOES NOT INCLUDE aspects of
adherence (diet, lab follow up, etc.) beyond pill-taking.
4 Hospital or Nursing Home Stay Any mention of a hospital or nursing home stay EXCEPT for CHF (because that has its own variable - see
below)
5 Nausea and Vomiting Any mention
6 Decreased PO Intake or
Decreased Appetite
Any mention
7 Diarrhea Any mention
8 Decompensated CHF Any mention of fluid overload, fluid retention, edema, pulmonary edema. Any titration of lasix doses, trending
of weight regarding fluid status, use of metolazone (i.e. zaroxolyn), or any obvious CHF regimen. Any hospital
admissions for fluid overload.
9 Alcohol Any mention of alcohol except “denies.” Exception - one serving per day or less does not count
10 Amiodarone Any mention of amiodarone or its brand names “pacerone” or “cordarone.”
11 Acetaminophen Any mention of acetaminophen, products containing acetaminophen. Includes the abbreviation “APAP.”
12 NSAIDS/COX-2 Inhibitors Any mention at all, including mention in the medication list.
13 Procedures Any mention of a procedure in conjunction with a dose reduction or a “hold” of warfarin - even if the
procedure is ultimately cancelled.
14 Cancer Any mention of cancer, with or without specific therapies such as chemotherapy, radiation, etc. DOES NOT
INCLUDE a mere history of cancer.
15 Missed Appointments Any recorded missed appointments - unless due to hospitalization (which is a different variable).
16 Systemic Corticosteroids Any mention. DOES NOT INCLUDE joint injections, skin creams, etc.
17 Alternative Medications Any mention - including but not limited to saw palmetto, St. John’s Wort, Echinacea, Coenzyme Q10, etc.
18 Antibacterial Antibiotics Any mention - must be systemic therapy, not local (such as skin creams, etc.)
For all items, one mention is sufficient to mark the item “yes.” Mark a “1” if present, or a “0” if absent.
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the cases and controls, respectively. Among the 69
patients with “other” indications for anticoagulation, 27
were anticoagulated for stroke, transient ischemic attack,
or cerebrovascular disease; 22 were anticoagulated for
congestive heart failure; 13 were anticoagulated for cor-
onary artery disease; 4 were anticoagulated for hypercoa-
gulability; and 3 were anticoagulated for other reasons.
Co-morbidities such as hypertension, diabetes, and cor-
onary artery disease were similar between groups.
Validation of Coefficient of Variation as a Measure of Risk
CoV corresponded well with other measures of anticoa-
gulation control and risk for adverse events. The 109
case patients had a mean TTR of 53%, compared to 79%
for the 218 control patients (p < 0.001). Cases had a
higher rate of adverse events. Six case patients experi-
enced major hemorrhage, compared to only 1 control
patient (p < 0.001). Three case patients had thromboem-
bolic events (2 embolic strokes and 1 pulmonary embo-
lism), compared to 0 control patients (p = 0.04).
Predictors of Dose Variability
We assessed predictors of dose variability using chart
review. The 3 reviewers achieved a very good rate of
inter-rater reliability (three-way  = 0.76). In the unad-
justed analysis (Table 3), most of the risk factors we
examined were associated with case status. Particularly
strong associations were seen with amiodarone (12 cases
vs. no controls, p < 0.001) and a diagnosis of cancer (8
cases vs. 1 control, p < 0.001). When present, these vari-
ables were highly indicative of high CoV.
After adjustment for covariates (Table 4), variables
independently associated with large dose variation
included hospital/nursing home stay (OR = 21.3),
decreased oral intake (OR = 12.2), use of systemic ster-
oids (OR = 6.1), use of acetaminophen (OR = 4.0), and
use of antibiotics (OR = 2.7). Effect size of amiodarone
and cancer could not be calculated because there were
too few controls with these variables. The presence of
these variables precluded model convergence; therefore,
these variables were omitted from the model.
Discussion
In this study, we have describe a new measure to identify
patients at risk for adverse outcomes of anticoagulation
care, have shown that the measure is correlated with INR
control and adverse events, and have examined patient-
level predictors of being in this high-risk group. The char-
acteristics independently predictive of large weekly varia-
tion in warfarin dose were hospitalization/nursing home
stay, decreased oral intake, use of systemic steroids, aceta-
minophen, and antibiotics. In addition, the use of amio-
darone and a diagnosis of cancer were almost certainly
risk factors for high CoV, though we could not estimate
an effect size.
This study suggests that CoV could be an important
tool for identifying patients at high risk for poorly con-
trolled anticoagulation therapy and adverse events.
Patients identified as high-risk might be referred for case
management, adherence training, more intensive follow-
up, or indeed reconsideration of whether this particular
patient is a good candidate for warfarin. The utility of
Table 2 Baseline patient characteristics compared
between cases (n = 109) and controls (n = 218)
Demographics Cases (%) Controls (%) P-value
Age 75 or Older 50 42 0.20*
Female 45 32 0.02*
Nonwhite Race 11 6 0.10*
Hypertension 48 47 0.99*
Diabetes 21 21 0.99*
Coronary Artery Disease 39 34 0.53*
Follow up time 10.9 months 11.5 months < 0.001†
# INR/month 2.3 1.2 < 0.001†
Indication: 0.26*
Atrial Fibrillation 67 58
VTE 11 13
Valvular Heart disease 6 5
Other 16 24
*Comparison via Monte Carlo simulation
†Comparison via Generalized Estimating Equations (GEE)
Table 3 Proportion of cases and controls with risk factors
for extreme dose variability (unadjusted results).
Risk Factors Cases
(n = 109)
Controls
(n = 218)
p-value*
Acetaminophen 33 (30%) 30 (14%) < 0.001
Adherence 48 (44%) 67 (31%) 0.01
Alcohol 9 (8%) 16 (7%) 0.99
Alternative Medication 11 (10%) 10 (5%) 0.08
Amiodarone 12 (11%) 0 (0%) < 0.001
Antibiotic Use 47 (43%) 44 (20%) < 0.001
Cancer 8 (7%) 1 (0%) < 0.001
CHF (Decompensated) 14 (13%) 7 (3%) 0.001
Decreased Oral Intake 21 (19%) 8 (4%) < 0.001
Diarrhea 15 (14%) 10 (5%) 0.003
Dietary Supplement 8 (7%) 6 (3%) 0.06
Dietary Vitamin K 40 (37%) 73 (34%) 0.61
Hospitalizations/Nursing Home 47 (43%) 12 (6%) < 0.001
Missed Appointments 12 (11%) 22 (10%) 0.99
Nausea/Vomiting 10 (9%) 5 (2%) 0.01
NSAID Use 19 (17%) 18 (8%) 0.02
Procedures 28 (26%) 41 (19%) 0.21
Systemic Steroids 12 (11%) 9 (4%) 0.03
All variables were obtained by chart review and all are yes/no variables.
Boldface variables are significant at the 0.05 level.
*Via Monte Carlo simulation
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examined in a prospective study. Anticoagulation control
(as measured by TTR) could also be used to prospectively
identify patients at high risk for adverse events. Our
study did not directly compare the ability of these two
measures (TTR vs. dose CoV) to identify patients at high-
est risk for adverse events; this would also be a suitable
topic for future study. We suspect that, in many care set-
tings, there is no effort to prospectively identify patients
at high risk of adverse events. If the utility of this
approach can be established, it may be more widely
employed.
An ideal next step to further this research would be to
use CoV to identify patients at high risk for poor out-
comes in the context of a quasi-experimental design. At
some sites of care, patients with extremely high CoV
might be referred for case management, adherence train-
ing, more intensive follow-up, or indeed reconsideration
of whether this particular patient is a good candidate for
warfarin. At other sites of care, CoV would be noted, but
not acted upon. The outcomes for patients with high CoV
(TTR and hopefully clinical outcomes) would be com-
pared, and the effectiveness and cost-effectiveness of the
intervention assessed.
Hospitalization had the strongest association with
unstable anticoagulation control of any variable in our
multivariate analysis. Being hospitalized can contribute
to variable dosing for several reasons. When patients are
hospitalized, warfarin therapy is often interrupted, and
patients may receive parenteral anticoagulation or no
anticoagulation at all. Hospitalization also involves large
changes in the patient’s lifestyle and diet. Returning
home, the patient attempts to re-establish usual habits
while often restarting warfarin therapy at the previous
dose. Unsurprisingly, this combination of circumstances
produces out-of-range INR values. Hospitalization is
also a general marker of illness severity, which can pre-
dict poorer anticoagulation control both before and
after hospitalization. Previous studies have also exam-
ined the event of a hospitalization as a time-dependent
inducer of variable anticoagulation control [23].
Several studies have shown an association with warfarin
and acetaminophen [24,25]. Hylek et al. [26] described
acetaminophen as an underrecognized source of INR ele-
vation. Her study which included a case-control prospec-
tive design assessed patients with high INR values (> 6.0).
Acetaminophen was noted as a risk factor that was docu-
mented only as case studies in the literature previously.
One study examined the prevalence of adverse warfarin-
drug combinations in a post-mortem toxicology database.
Acetaminophen accounted for more than half of the war-
farin drug interactions. In that study, there were more
deaths with the combination of acetaminophen and war-
farin than with either drug alone [27]. Despite these data,
discordant findings showing lack of an association with
acetaminophen and warfarin potentiation have been
reported [28-30]. The present study reinforces the theory
that the use of acetaminophen can contribute to poor
anticoagulation control.
Several other studies have described factors associated
with anticoagulation control [31-33]. One study, similar
to ours, examined factors that contribute to unstable
control and found no association with dietary habits or
the presence of comorbid conditions. Instead, they found
greater instability among patients working full-time,
among those with inadequate understanding of oral
anticoagulation therapy, and among those with
CYP2c9*3 variants [31]. Other studies have examined
factors associated with extremely stable control. Witt et
al. [32,33] performed 2 studies looking at patients that
spent 100% of the time in therapeutic range. Both studies
found that older age, lack of co-morbidities and a stan-
d a r dI N Rt a r g e tr a n g e( i . e .2 - 3 )w e r ea s s o c i a t e dw i t h
stable control.
There are several strengths to our study. We used a
large, nationally representative database of patients
receiving warfarin in community-based practice. Our
three chart reviewers achieved a very good rate of inter-
rater reliability. Finally, this database (ACTION) contains
weekly warfarin doses for all patients. These data are
usually not available, since warfarin is often prescribed
Table 4 Multivariate analysis of risk factors for extreme
warfarin variability
Chart Review Variables Odds Ratio (95% CI) p-value
Acetaminophen 4.0 (1.33 to 6.30) 0.01
Adherence 2.0 (0.87 to 4.65) 0.10
Alcohol 2.5 (0.65 to 10.00) 0.18
Alternative Medication 2.0 (0.38 to 9.63) 0.44
Amiodarone * *
Antibiotic Use 2.7 (1.11 to 6.33) 0.03
Cancer * *
CHF (Decompensated) 2.0 (0.34 to 11.58) 0.44
Decreased Oral Intake 12.2 (2.25 to 65.68) 0.004
Diarrhea 2.8 (0.51 to 15.67) 0.23
Dietary Supplement 1.0 (0.12 to 7.90) 0.98
Dietary Vitamin K 2.1 (0.86 to 4.92) 0.10
Hospitalizations/Nursing Home 21.3 (6.21 to 73.14) < 0.001
Missed Appointments 1.6 (0.51 to 5.15) 0.42
Nausea/Vomiting 4.4 (0.70 to 27.91) 0.11
NSAID Use 1.3 (0.36 to 4.72) 0.69
Procedures 1.4 (0.59 to 3.36) 0.44
Systemic Steroids 6.1 (1.10 to 34.20) 0.04
Variables are adjusted for all other variables in the table, as well as for age,
gender, race, and comorbid conditions (not shown).
* These variables were not estimable in the multivariate model, because too
few control patients had these characteristics. Therefore, these variables were
omitted from the model.
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abstracted. This is a unique feature of this database, with-
out which we could not have performed this study.
Despite this our study has some limitations. First, this
study did not address the question of whether high dose
variability is a cause or a consequence of poor anticoagu-
lation control, although we would suspect that it is pre-
dominantly a consequence of it. Nevertheless, this study
does demonstrate that dose variability is both measurable
and related to important clinical outcomes, regardless of
its causal relationship with anticoagulation control. As
such, it might be used to identify patients at elevated risk
for adverse events. Second, this study was limited to risk
factors for high CoV that were clearly documented in the
clinical notes; however, some risk factors may have been
present, but poorly recognized or poorly documented.
Our results with regard to risk factors for high CoV
should be regarded as exploratory, particularly where a
risk factor was shown not to predict high CoV, because
an absence of documentation is not conclusive proof that
something did not occur. Third, we emphasize that we
have only subjected our new scoring system to internal
validation, i.e. within the same dataset. A higher level of
validation would be attained by demonstrating its utility
in a separate dataset. Fourth, the confidence intervals
identified in our multivariable analysis of patient-level
risk factors for high dose variability are quite large.
Therefore, the true magnitude of these effects is not pre-
cisely known. A final limitation is that this study evalu-
ates patients with a target INR range of 2-3 and at least 1
month of experience with warfarin; our study results may
not apply to patients who are new to warfarin or those
with other target ranges.
Conclusions
In this study, we have derived and internally validated a
new measure to identify patients at high risk for poor
anticoagulation control in clinical practice, namely the
coefficient of variation of weekly warfarin doses. This
measure identifies patients at high risk for poor anticoa-
gulation control and adverse events. Future studies
should explore the use of this measure to identify
patients for intervention before they have experienced an
adverse event.
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